2020
Lyme disease: diagnosis and treatment.
Schoen R. Lyme disease: diagnosis and treatment. Current Opinion In Rheumatology 2020, 32: 247-254. PMID: 32141956, DOI: 10.1097/bor.0000000000000698.Peer-Reviewed Original ResearchConceptsClinical manifestationsLyme arthritisAdjunctive laboratory testsAcute systemic illnessLyme diseaseDiagnosis of Lyme diseaseTreatment of Lyme diseaseOligo-arthritisUntreated patientsClinical featuresAntibiotic treatmentSystemic illnessRheumatic diseasesInflammatory arthritisTreatment approachesRheumatoid arthritisDiagnostic testsPatientsArthritisDiseaseManifestationsTreatmentVector-borne infectionsLaboratory testsLymeChallenges in the Diagnosis and Treatment of Lyme Disease
Schoen R. Challenges in the Diagnosis and Treatment of Lyme Disease. Current Rheumatology Reports 2020, 22: 3. PMID: 31912251, DOI: 10.1007/s11926-019-0857-2.Peer-Reviewed Original ResearchConceptsTreatment of Lyme diseaseClinical featuresCourse of oral antibiotic therapyOral antibiotic therapyLate-stage manifestationLate-stage diseaseLyme diseaseAntibiotic therapyCausative organismTreatment strategiesClinical expressionLyme arthritisImpact of Lyme diseaseDiagnosisDiseasePatientsTreatmentVector-borne illnessStrains of Borrelia burgdorferiLymeWell-characterizedMorbidityTherapyFindingsIt
2007
Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis
Pal U, Wang P, Bao F, Yang X, Samanta S, Schoen R, Wormser GP, Schwartz I, Fikrig E. Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis. Journal Of Experimental Medicine 2007, 205: 133-141. PMID: 18166585, PMCID: PMC2234379, DOI: 10.1084/jem.20070962.Peer-Reviewed Original ResearchConceptsLyme arthritisMouse jointsB. burgdorferi antigensBurgdorferi-infected miceSevere arthritisSpirochete numbersArthritisHost responseLyme diseaseAffinity-purified antibodiesBorrelia burgdorferiChain reactionMiceOriginal phenotypeBasic membrane proteinMutant spirochetesGene expressionJointsInflammationPathogenesisAntigenDiseaseB. burgdorferi gene expression
2005
A comparison of two treatment regimens of ceftriaxone in late Lyme disease
Dattwyler R, Wormser G, Rush T, Finkel M, Schoen R, Grunwaldt E, Franklin M, Hilton E, Bryant G, Agger W, Maladorno D. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wiener Klinische Wochenschrift 2005, 117: 393-397. PMID: 16053194, DOI: 10.1007/s00508-005-0361-8.Peer-Reviewed Original ResearchConceptsLate Lyme diseaseDays of therapyLyme diseaseSerologic criteriaClinical cure rateMulti-center studyEvaluable patientsOpen labelAdverse eventsClinical responseClinical subsetsTreatment failureTreatment regimensCure rateEntry criteriaObjective abnormalitiesSerologic resultsSerologic reactivityPatientsLast evaluationOptimal durationCeftriaxoneDiseaseTherapyBorrelia burgdorferi
2000
The Lyme disease vaccine: conception, development, and implementation.
Thanassi W, Schoen R. The Lyme disease vaccine: conception, development, and implementation. Annals Of Internal Medicine 2000, 132: 661-8. PMID: 10766685, DOI: 10.7326/0003-4819-132-8-200004180-00009.Peer-Reviewed Original Research
1999
Successful vaccination for Lyme disease:a novel mechanism
Thanassi W, Schoen R. Successful vaccination for Lyme disease:a novel mechanism. Expert Opinion On Investigational Drugs 1999, 8: 29-35. PMID: 15992056, DOI: 10.1517/13543784.8.1.29.Peer-Reviewed Original Research
1998
Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant
Steere A, Sikand V, Meurice F, Parenti D, Fikrig E, Schoen R, Nowakowski J, Schmid C, Laukamp S, Buscarino C, Krause D. Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant. New England Journal Of Medicine 1998, 339: 209-215. PMID: 9673298, DOI: 10.1056/nejm199807233390401.Peer-Reviewed Original ResearchConceptsLyme diseaseSerologic testingVaccine efficacyAsymptomatic infectionLipoprotein AInjections of vaccineOuter surface lipoprotein AB. burgdorferi infectionFirst yearPlacebo recipientsPlacebo groupVaccine groupVaccine recipientsStudy entryRandomized trialsSystemic reactionsThird injectionBurgdorferi infectionEffective vaccineSkin lesionsReaction testingVaccineDefinite casesDiseaseInfection
1994
IDENTIFICATION OF LYME DISEASE
Schoen R. IDENTIFICATION OF LYME DISEASE. Rheumatic Disease Clinics Of North America 1994, 20: 361-369. PMID: 8016416, DOI: 10.1016/s0889-857x(21)00053-3.Peer-Reviewed Original ResearchConceptsLate Lyme diseaseLyme diseaseSerologic testingMinority of patientsEarly Lyme diseaseChronic meningitisMost patientsRheumatic diseasesEarly diseaseChronic fatigueSuccessful treatmentDisease manifestationsHigh indexDiseasePatientsB. burgdorferiMost individualsAntibioticsTreatmentIndividualsOligoarthritisMeningitisRashSeroreactivityClinicians
1989
Relapsing or reinfectious lyme hepatitis
Schoen R. Relapsing or reinfectious lyme hepatitis. Hepatology 1989, 9: 335-336. PMID: 2912832, DOI: 10.1002/hep.1840090229.Peer-Reviewed Original Research
1987
The clinical evolution of Lyme arthritis.
Steere A, Schoen R, Taylor E. The clinical evolution of Lyme arthritis. Annals Of Internal Medicine 1987, 107: 725-31. PMID: 3662285, DOI: 10.7326/0003-4819-107-5-725.Peer-Reviewed Original ResearchConceptsLyme arthritisClinical evolutionDisease onsetIntermittent attacksSubjective joint painErythema chronicum migransFrank arthritisChronic synovitisErosive diseaseJoint painAntibiotic therapyMusculoskeletal painJoint disabilityMean durationJoint abnormalitiesLarge jointsArthritisPatientsLyme diseaseSubsequent manifestationBrief episodesPainDiseaseEpisodesOnsetTreatment of Lyme disease
Steere A, Green J, Hutchinson G, Rahn D, Pachner A, Schoen R, Sigal L, Taylor E, Malawista S. Treatment of Lyme disease. International Journal Of Medical Microbiology 1987, 263: 352-356. PMID: 3109144, DOI: 10.1016/s0176-6724(87)80092-5.Peer-Reviewed Original ResearchConceptsPenicillin-treated patientsLyme diseaseHigh-dose intravenous penicillinAttacks of arthritisIntravenous penicillin GHalf of patientsMajor late complicationsEarly Lyme diseaseIntramuscular benzathine penicillinIntravenous penicillinLate complicationsAntibiotic therapyArthritis patientsBenzathine penicillinMotor deficitsNeurologic abnormalitiesLate diseaseLate symptomsPatientsPhenoxymethyl penicillinAntibiotic agentsComplete recoveryDiseasePenicillin GArthritis